Cell-Free DNA Analysis for the Determination of Fetal Red Blood Cell Antigen Genotype in Individuals With Alloimmunized Pregnancies.
Shannon Rego, Olaide Ashimi Balogun, Kirsten Emanuel...
https://pubmed.ncbi.nlm.nih.gov/39053010/Actively Recruiting
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
120
Participants Needed
69
Research Sites
113 weeks
Total Duration
Researchers are evaluating the use of nipocalimab in pregnant individuals at risk for severe Hemolytic Disease of the Fetus and Newborn HDFN. The study aims to compare nipocalimab with a placebo to see if it can reduce the risk of fetal anemia, a condition where the babys red blood cell levels drop too low during pregnancy. This phase 3, randomized, placebo-controlled, and triple-blind study is conducted across multiple centers. Participants will receive either nipocalimab or a matching placebo through weekly intravenous infusions starting from randomization until 35 weeks of gestational age. The study groups include an experimental group receiving nipocalimab and a placebo group receiving an inactive treatment, both administered once weekly. The study timeline spans from randomization during weeks 13 to 18 of pregnancy through delivery and includes follow-up through the neonatal period and beyond. Participants will undergo various assessments including lab tests, fetal DNA testing, and monitoring of maternal and neonatal health outcomes. Researchers will measure the percentage of pregnancies without fetal loss, intrauterine transfusions, hydrops fetalis, or neonatal death, among many other maternal and infant health parameters. Follow-up extends to 104 weeks for some infant assessments, including growth and development, while maternal safety and pregnancy complications are also monitored up to 24 weeks postpartum. This comprehensive monitoring aims to capture the effect of nipocalimab on both mother and baby throughout pregnancy and after birth.
CONDITIONS
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
S
Study Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Janssen Research & Development, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Nipocalimab (investigational) | Placebo (trial comparator) | Current standard‑of‑care |
|---|---|---|---|
| What it is | An investigational FcRn‑blocking monoclonal antibody given by intravenous infusion every week during pregnancy | A placebo intravenous infusion given by chance in place of nipocalimab | Current management includes antenatal monitoring, intravenous immunoglobulin, and intrauterine transfusions |
| Role in trial | Investigational treatment being evaluated for preventing severe HDFN outcomes | Control arm serving as comparator to assess nipocalimab effect | Represents usual clinical approach used outside of trials for similar patients |
| Primary purpose | To reduce fetal loss, intrauterine transfusion, hydrops, or neonatal death in high‑risk pregnancies | Serves to assess effectiveness by comparison with no active intervention | Manage severe HDFN by treating fetal anemia and preventing fetal/neonatal complications |
| How it is given or performed | Administered by intravenous infusion weekly during mid‑to‑late pregnancy | Delivered by intravenous infusion weekly, similar to study drug | Includes fetal monitoring via ultrasound and immunologic testing; intrauterine transfusions when indicated |
| Evidence status | Phase 2 UNITY study showed 54% of high‑risk pregnancies had live births without IUT versus historical 0% benchmark | No efficacy data—serves as control in ongoing study | IUT achieves fetal survival rates up to 97% but is invasive and technically complex |
| Important risks | Potential serious adverse events observed in mothers and infants in Phase 2 UNITY; infant infections were mild to moderate | No safety risk from placebo beyond protocol‑related procedures | Intrauterine transfusions carry procedural risks, increased before 24 weeks’ gestation |
| Important limitations | Efficacy based on phase 2 open‑label study compared with historical controls; phase 3 results pending | No direct clinical benefit; serves only as benchmark in randomized design | Requires specialized centres for IUT and carries procedural risk; not preventive |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From randomization until 35 weeks of gestational age
Participants receive weekly intravenous infusions of either nipocalimab or a placebo from randomization through 35 weeks of pregnancy.
Weekly visits for infusions
Duration - Up to 104 weeks after birth
Participants and their babies are monitored for health outcomes and safety through delivery and postpartum, including assessments up to 104 weeks after birth for infants.
Regular visits and assessments during postpartum and infant follow-up
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Shannon Rego, Olaide Ashimi Balogun, Kirsten Emanuel...
https://pubmed.ncbi.nlm.nih.gov/39053010/Janssen Research & Development, LLC
Lead Sponsor